Advertisement

Diabetogenic Potential of Human Pathogens Uncovered in Experimentally Permissive β-Cells

  1. Malin Flodström,
  2. Devin Tsai,
  3. Cody Fine,
  4. Amy Maday and
  5. Nora Sarvetnick
  1. From the Department of Immunology, the Scripps Research Institute, La Jolla, California
  1. Address correspondence and reprint requests to Nora Sarvetnick, Department of Immunology (IMM-23), the Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. E-mail: noras{at}scripps.edu

Abstract

Pancreatic β-cell antiviral defense plays a critical role in protection from coxsackievirus B4 (CVB4)-induced diabetes. In the present study, we tested the hypothesis that interferon (IFN)-induced antiviral defense determines β-cell survival after infection by the human pathogen CVB3, cytomegalovirus (CMV), and lymphocytic choriomeningitis virus (LCMV). We demonstrated that mice harboring β-cells that do not respond to IFN because of the expression of the suppressor of cytokine signaling-1 (SOCS-1) succumb to an acute form of type 1 diabetes after infection with CVB3. Interestingly, the tropism of the virus was altered in SOCS-1 transgenic (Tg) mice, and CVB3 was detected in islet cells of SOCS-1–Tg mice before β-cell loss and the onset of diabetes. Furthermore, insulitis was increased in SOCS-1–Tg mice after infection with murine CMV, and a minority of the mice developed overt diabetes. However, infection with LCMV failed to cause β-cell destruction in SOCS-1 Tg mice. These findings suggest that CVB3 can cause diabetes in a host lacking adequate β-cell antiviral defense, and that incomplete target cell antiviral defense may enhance susceptibility to diabetes triggered by CMV. In conclusion, suppressed β-cell antiviral defense reveals the diabetogenic potential of two pathogens previously linked to the onset of type 1 diabetes in humans.

Footnotes

  • M.F. is currently affiliated with the Department of Medicine, Center for Infectious Medicine, The Karolinska Institute, Haddinge University Hospital, Stockholm, Sweden.

    • Accepted April 30, 2003.
    • Received January 29, 2003.
| Table of Contents
Advertisement